PASI 100 response to secukinumab in primary failure to ustekinumab: analysis of cost‐effectiveness among biological drugs-Reference-Cited by-同舟云学术

PASI 100 response to secukinumab in primary failure to ustekinumab: analysis of cost‐effectiveness among biological drugs

Published:2021-05-02 Issue:9 Volume:60 Page:1165-1167
ISSN:0011-9059
Container-title:International Journal of Dermatology
language:en
Short-container-title:Int J Dermatol

Author:

Oliveira Maria de Fátima P.¹,Rocha Bruno de O.¹²³⁴^ORCID,Duarte Gleison V.⁵

Affiliation:

1. Department of Dermatology University Hospital Complex Prof. Edgard Santos The Federal University of Bahia (C‐HUPES/UFBa) Salvador Bahia Brazil

2. Aristides Maltêz Hospital The Bahia’s League Against Cancer (HAM‐LBCC) Salvador Bahia Brazil

3. The Holy Family Hospital Sister Dulce Social Works (HSF‐OSID) Salvador Bahia Brazil

4. Integrated Center for Education and Health (CIES) –UniFTC Salvador Bahia Brazil

5. Instituto Bahiano de Imunoterapia (IBIS) Salvador Bahia Brazil

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.15493

Reference12 articles.

1. WHO psoriasis report.2016. Available at:http://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189‐por.pdf?sequence=17&isAllowed=y. Accessed 08 September 2018.

2. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab

3. Methods Report: European S3-Guidelines on the systemic treatment of psoriasis vulgaris - update 2015 - EDF in cooperation with EADV and IPC

4. Respuesta a secukinumab tras fracaso terapéutico con ustekinumab en seis pacientes con psoriasis en placas

5. Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ustekinumab;Reactions Weekly;2021-11